Evommune
EVMN and MEHAThe company is a manufacturer and distributor of high-purity nutraceutical supplements, specializing in hypoallergenic formulations for sensitive populations and the special needs community.
Earnings
Next report
Aug 6, 2026 (in a month)Valuation & ratios
Segments
By product
Competitors
By market cap
By revenue growth
By net margin
Profile
The company is a manufacturer and distributor of high-purity nutraceutical supplements, specializing in hypoallergenic formulations for sensitive populations and the special needs community. It operates a vertically integrated model with an FDA-registered, cGMP-certified manufacturing facility and a digitally native health platform. The business focuses on delivering science-backed nutritional solutions across multiple channels, including direct-to-consumer, wholesale, and international distribution.
The company distinguishes itself through a 70-year brand heritage in the autism community and a commitment to purity standards that exceed FDA requirements for dietary supplements.
Questions, answered.
- What is Evommune 's market cap?
- Evommune (EVMN) has a market capitalization of $848.6M and trades on NYSE.
- What is Evommune 's revenue and profitability?
- Evommune generated $6.7M in trailing twelve-month revenue with a net loss of $6.0M, representing a net margin of -90.1%. Gross margin stands at 53.7%. These figures are based on the Q1 2026 filing.
- Who are Evommune 's competitors?
- Evommune 's key competitors include Centrum, Bausch + Lomb, BillionToOne, Inc. Class A Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Evommune partner with?
- Evommune 's notable partners include CareValidate, Market Performance Group, The FORUM, and others.
- What subsidiaries does Evommune have?
- Evommune 's subsidiaries include HTO Nevada, Functional Brands Inc..
- Where is Evommune headquartered?
- Evommune is headquartered in United States of America. It has been publicly traded since 2025.
